20 citations
,
December 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.
July 2025 in “Pharmaceutics” Recombinant Human Annexin A5 may help treat localized scleroderma by reducing skin thickening and inflammation.
April 2007 in “Nature Clinical Practice Urology” TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.
12 citations
,
March 2016 in “Life Sciences” The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.
20 citations
,
March 2019 in “Case Reports in Dermatology” IL-17 inhibitors for psoriasis may cause unexpected hair loss.
March 2026 in “The American Journal of Managed Care” JAK inhibitors can help treat alopecia areata but have risks and high costs.
26 citations
,
October 2020 in “Pediatric Dermatology” Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
3 citations
,
January 2000 in “Journal of Dermatological Treatment” Oral calcitriol helped improve scleroderma and hair regrowth in a young woman.
October 2025 in “Figshare” Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
July 2025 in “Journal of Investigative Dermatology” Upadacitinib effectively treats pyoderma gangrenosum.
73 citations
,
March 2014 in “Journal of The American Academy of Dermatology” Most dermatologic medications are safe during pregnancy and breastfeeding, but some should be avoided due to potential risks.
15 citations
,
July 2010 in “Journal of Allergy and Clinical Immunology” A new cream, DHMEQ, reduces allergic skin inflammation effectively.
December 2015 in “OPAL (Open@LaTrobe) (La Trobe University)” QLT0267 stops hair follicle cell growth and movement.
January 2016 in “Chemistry & Industry” Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.
March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
5 citations
,
June 2001 in “Annals of Internal Medicine” Rituximab effectively treated a woman's bone lymphoma that was resistant to other treatments.
37 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Ruxolitinib can help regrow hair in severe alopecia areata.
April 2025 in “JAAD Case Reports” Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.
5 citations
,
April 2020 in “Journal of The American Academy of Dermatology” Hydroxychloroquine might help prevent COVID-19, but more research is needed.
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
February 2026 in “Journal of Drugs in Dermatology” Dupilumab helped a 13-year-old regrow hair after alopecia totalis.
15 citations
,
August 2002 in “British Journal of Ophthalmology” Intralesional cidofovir might be a viable alternative treatment for certain conditions.
January 2021 in “Mastology” Scalp cooling therapy helped over 80% of women keep at least half their hair during chemotherapy.
January 2025 in “Frontiers in Pediatrics” Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.
2 citations
,
October 2022 in “Dermatologic Therapy” Baricitinib may effectively treat lichen planopilaris.
1 citations
,
August 2022 in “Journal of Dermatology and Dermatologic Surgery” A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.
6 citations
,
September 2024 in “Current Oncology” Sacituzumab Govitecan is effective for certain breast cancers but requires careful management of side effects.
April 2026 in “Clinical and Experimental Dermatology” Dupilumab effectively reduces symptoms of prurigo nodularis and is safe for long-term use.
12 citations
,
August 2019 in “Dermatitis” Dupilumab for skin problems might reactivate hair loss in some patients.
July 2025 in “Journal of Investigative Dermatology” Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.